Drug intelligence / Profile preview

ADARE-214

Development stage: Preclinical
Lead developer: Daré Bioscience
Modality: Drug Delivery Systems, Small Molecules
Administration: Injectable

Overview

ADARE-214 is a long-acting injectable contraceptive candidate developed by Daré Bioscience in collaboration with Adare Pharma Solutions. It is designed to provide 12-month contraception using etonogestrel, delivered via Adare's proprietary microsphere technology for extended release. The development aims to understand women's preferences to inform its target product profile. Etonogestrel, a progestin, works by preventing ovulation, thickening cervical mucus, and thinning the endometrium to prevent pregnancy.

Targets

PR (Progesterone receptor)

Beyond the preview

Go deeper on ADARE-214.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ADARE-214.

Explore the full profile